Peptides›GH secretagogue›GHRP-6

GHRP-6

/ Synthetic hexapeptide; ghrelin / GHS-R1a receptor agonist; first characterized GHRP

SPECULATIVEN = 0 · TESTING PENDINGLAST REVIEW 2026·04·20

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequence— sequence not captured —

MW · —CLASS · Synthetic hexapeptide; ghrelin / GHS-R1a receptor agonist; first characterized GHRPCATEGORY · GH secretagogue

Historical first-generation growth hormone-releasing peptide. Not in modern pharmaceutical development. Substantial appetite stimulation and cortisol/prolactin side effects.

§ B · Mechanism of action

GHRP-6 was one of the first characterized synthetic growth hormone-releasing peptides (Bowers 1984). It acts at the ghrelin/GHS-R1a receptor but is notable for pronounced appetite stimulation — a direct reflection of ghrelin-mimetic activity.

§ C · Human clinical evidence

Foundational pharmacology studies exist; no ongoing pharmaceutical development. Largely superseded by ipamorelin (selective) and MK-677 (oral) in modern GH-secretagogue research.

§ D · Primary literature

PubMed6426923Bowers CY et al. — On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone · Endocrinology · other-animalOriginal characterization of growth hormone-releasing peptides (GHRPs) including the hexapeptide lineage. Foundation for GHRP-2, GHRP-6, hexarelin, and subsequent ghrelin-mimetic development.Limitations: Preclinical; predates identification of ghrelin (1999) as the endogenous ligand for these receptor agonists.1984

§ F · Safety signal

Pronounced appetite stimulation. Cortisol and prolactin elevation. Flushing. No long-term human safety data at chronic doses. Limited modern human safety evaluation.

§ H · Regulatory status

Regulatory status

FDA status:: Not FDA-approved

§ I · Notable gaps and controversies

GHRP-6 is historically important but largely obsolete in current GH-secretagogue research. Its continued presence in the research-chemical market reflects commodity production rather than scientific priority.